The therapeutic efficacy and safety of compound Kushen injection combined with transarterial chemoembolization in unresectable hepatocellular carcinoma: An update systematic review and meta-analysis

Frontiers in Pharmacology

Volumn 7, Issue MAR, 2016, Pages

  Ma, Xiao ^a,b   Li, Rui Sheng ^a   Wang, Jian ^b   Huang, Yin Qiu ^a,b   Li, Peng Yan ^a   Wang, Ji ^c   Su, Hai Bin ^a   Wang, Rui Lin ^a   Zhang, Ya Ming ^a   Liu, Hong Hong ^a   Zhang, Cong En ^a,b   Ma, Zhi Jie ^d   Wang, Jia Bo ^a   Zhao, Yan Ling ^a   Xiao, Xiao He ^a  

^a 302 MILITARY HOSPITAL   (China)

^b CHENGDU UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Compound Kushen Injection; Meta analysis; Systematic review; Transarterial chemoembolization; Unresectable hepatocellular carcinoma

Indexed keywords

10 HYDROXYCAMPTOTHECIN; AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; COMPOUND KUSHEN INJECTION; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINATE CALCIUM; HERBACEOUS AGENT; MITOMYCIN; PIRARUBICIN; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CHINESE MEDICINE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER PAIN; META ANALYSIS; NAUSEA; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 84973131587     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00070     Document Type: Review

References (46)

1. Cabrera, R., Pannu, D. S., Caridi, J., Firpi, R. J., Soldevila-Pico, C., Morelli, G., et al. (2011). The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment. Pharmacol. Ther. 34, 205-213. doi: 10.1111/j.1365-2036.2011.04697.x
2. Cammá, C., Schepis, F., Orlando, A., Albanese, M., Shahied, L., Trevisani, F., et al. (2002). Transarterial chemoembolisation for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224, 47-54. doi: 10.1148/radiol.2241011262
3. Cao, J., Wang, Z., Fang, J., Liu, H., and He, Y. (2009). Clinical study of compound kushen injection combined with TACE for treatment of advanced liver cancer. Shandong Med. 49, 74-76.
4. Chen, H., Li, S., and Yang, L. (2007). Therapeutic effects of complex kushen injection combined with double interventional therapy on treating primary hepatocarcinoma. Chin. J. Integr. Tradit. Western Med. Digest. 15, 239-241.
5. Cheung, F., Wang, X., Wang, N., Yueu, M.-F., Ziea, T.-C., Tong, Y., et al. (2013). Chinese medicines as an adjuvant therapy for unresectable hepatocellular carcinoma during transarterial chemoembolization: a meta-analysis of randomized controlled trials. Evid Based Compl. Alternat Med. 2013:487919. doi: 10.1155/2013/487919
6. Deeks, J. J., Higgins, J. P. T., Altman, D. G., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available at: http://www.cochrane-handbook.org.
7. Deng, L., Li, Z., and Wu, Y. (2009). Therapeutic effect of continuous infusion of compound kushen injection combined with hepatic arterial chemoembolization for advanced liver cancer: an observation of 20 cases. J. New Chin. Med. 41, 28-29.
8. El-Serag, H. B. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264-1273. doi: 10.1053/j.gastro.2011.12.061
9. European Association for the Study of The Liver and European Organisation For Research and Treatment Of Cancer (2012). EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943. doi: 10.1016/j.jhep.2011.12.001
10. Forner, A., Llovet, J. M., and Bruix, J. (2012). Hepatocellular carcinoma. Lancet 379, 1245-1255. doi: 10.1016/S0140-6736(11)61347-0
11. Han, W., Yuan, C., and Zhang, T. (2012). Clinical efficacy and immunologic function observation of TACE plus compound Kushen injection for hepatocellular carcinoma patients. Chin J. Tradit. Med. Sci. Technol. 19, 61-62.
12. Higgins, J. P., Thompson, S. G., Deeks, J. J., and Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ 327, 557-560. doi: 10.1136/bmj.327.7414.557
13. Huang, R., Chen, S., Huang, X., and Li, Y. (2006). Clinical observation on advanced primary hepatic carcinoma treated by yanshu injection combined with transcatheter arterial chemoembolization. Hebei Med. 12, 443-445.
14. Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W. Y., Takayama, T., et al. (2011). Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer 47, 2117-2127. doi: 10.1016/j.ejca.2011.05.007
15. Lammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., et al. (2010). Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol. 33, 41-52. doi: 10.1007/s00270-009-9711-7
16. Li, B., Liu, Z., Li, L., Ma, L., Zhou, Z., and Hu, W. (2013). Efficacy analysis on 98 cases of hepatocellular carcinoma patients treated with compound Kushen injection combined with transarterial chemoembolization. J. Guiyang Coll. Tradit. Chin. Med. 35, 90-92.
17. Liu, L., Chen, H., Wang, M., Zhao, Y., Cai, G., Qi, X., et al. (2014). Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS ONE 9:e91124. doi: 10.1371/journal.pone.0091124
18. Llovet, J. M., and Bruix, J. (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37, 429-442. doi: 10.1053/jhep.2003.50047
19. Llovet, J. M., and Hernandez-Gea, V. (2014). Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin. Cancer Res. 20, 2072-2079. doi: 10.1158/1078-0432.CCR-13-0547
20. Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., et al. (2002). Arterial embolization or chemoembolisa-tion versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359, 1734-1739. doi: 10.1016/S0140-6736(02)08649-X
21. Lo, C. M., Ngan, H., Tso, W. K., Liu, C. L., Lam, C. M., Poon, R. T., et al. (2002). Randomised controlled trial of transarteriallipiodol chemoembolisation for unresectable hepatocellular carcinoma. Hepatology 35, 1164-1171. doi: 10.1053/jhep.2002.33156
22. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128. doi: 10.1016/S0140-6736(12)61728-0
23. Ma, L., Wen, S., Zhan, Y., He, Y., Liu, X., and Jiang, J. (2008). Anticancer effects of the Chinese medicine matrine on murine hepatocellular carcinoma cells. Planta Med. 74, 245-251. doi: 10.1055/s-2008-1034304
24. Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151, 264-269. doi: 10.7326/0003-4819-151-4-200908180-00135
25. Park, J. W., Koh, Y. H., Kim, H. B., Kim, H. Y., An, S., Choi, J. I., et al. (2012). Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J. Hepatol. 56, 1336-1342. doi: 10.1016/j.jhep.2012.01.006
26. Parvez, M. K., Arbab, A. H., Al-Dosari, M. S., and Al-Rehaily, A. J. (2016). Antiviral natural products against chronic hepatitis B: recent developments. Curr. Pharm. Des. 22, 286-293. doi: 10.2174/1381612822666151112152733
27. Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., et al. (2013). Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 31, 3501-3508. doi: 10.1200/JCO.2012.44.5643
28. Qu, Y., Tian, S., and Zhang, W. (2011). Therapeutic effect of TACE combined with compound sophora flavescens injection in mid and advanced stage primary liver cancer. China Pharm. 22, 1072-1074.
29. Sergio, A., Cristofori, C., Cardin, R., Pivetta, G., Ragazzi, R., Baldan, A., et al. (2008). Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am. J. Gastroenterol. 103, 914-921. doi: 10.1111/j.1572-0241.2007.01712.x
30. Sun, M. (2014). Treatment efficacy of TACE plus compound Kushen injection on hepatocellular carcinoma patients. Asia Pacific Tradit. Med. 10, 45-46.
31. Sun, M., Cao, H., Sun, L., Dong, S., Bian, Y., Han, J., et al. (2012). Antitumor activities of kushen: literature review. Evid Based Compl. Alternat Med. 2012:373219. doi: 10.1155/2012/373219
32. Sun, Q., Ma, W., Gao, Y., Zheng, W., Zhang, B., and Peng, Y. (2011). Meta-analysis: therapeutic effect of transcatheter arterial chemoembolization combined with compound kushen injection in hepatocellular carcinoma. Afr. J. Tradit. Compl. Altern Med. 9, 178-188.
33. Terzi, E., Golfieri, R., Piscaglia, F., Galassi, M., Dazzi, A., Leoni, S., et al. (2012). Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". J. Hepatol. 57, 1258-1267. doi: 10.1016/j.jhep.2012.07.025
34. Tian, Y. (2014). Clinical study of compound Kushen injection combined with transarterial chemoembolization for hepatocellular carcinoma patients. Contemp. Med. Forum 12, 45-46.
35. Tong, H. (2010). The observation of the clinical effects of transcatheter arterial chemoembolization and complex prescrption kuseng injection on the advanced period of liver cancer. Jiangxi Med. J. 45, 637-639.
36. Wang, H., and Chen, X. (2009). Composite Kushen injection combined with hepatic artery embolism on unresectable primary liver cancer. Mod. J. Integr. Tradit. Chin. Western Med. 18, 1334-1335.
37. Wang, W., You, R. L., Qin, W. J., Hai, L. N., Fang, M. J., Huang, G. H., et al. (2015). Anti-tumor activities of active ingredients in Compound Kushen Injection. Acta Pharmacol. Sin. 36, 676-679. doi: 10.1038/aps.2015.24
38. Wang, Y., Fang, H., Wang, X., and Zhou, K. (2011). Clinical observation of combination treatment with compound Kushen injection plus transarterial chemoembolization in hepatocellular carcinoma patients treated. Shandong Med. J. 51, 88-89.
39. Xu, P., Wang, W., Lu, J., and Fan, C. (2010). Efficacy of compound kushen injection in the prevention and treatment of the adverse reactions following transcatheter hepatic arterial chemoembolization in patient with liver cancer. Eval. Anal. Drug Hospit. China 10, 457-458.
40. Yang, S. (2006). Yan shu injecdtion combined with chemotherapy on treating advanced primary liver cancer. Public Med. Forum Magazine 10, 39-40.
41. Yu, L., Jiang, Y., and Li, G. (2009). Clinical efficacy and safety of compound Kushen Injection combined with TACE on patients with hepatocellular carcinoma. China Pract. Med. 4, 74-75.
42. Yu, M., and Kang, X. (2010). Efficacy of compound Kushen injection combined with TACE on treatment of hepatocellular carcinoma. Guide China Med. 8, 123-125.
43. Zhang, L., and Tian, Y. (2011). Efficacy and safety of composite matrine injection combined with TACE in the treatment of patients with liver carcinoma. Chin. J. New Drugs. 20, 2003-2009.
44. Zhang, Z., Wang, X., Wu, W., Wang, J., Wang, Y., Wu, X., et al. (2012). Effects of matrine on proliferation and apoptosis in gallbladder carcinoma cells (GBC-SD). Phytother. Res. 26, 932-937. doi: 10.1002/ptr.3657
45. Zhou, S. K., Zhang, R. L., Xu, Y. F., and Bi, T. N. (2012). Antioxidant and immunity activities of Fufang Kushen Injection Liquid. Molecules 17, 6481-6490. doi: 10.3390/molecules17066481
46. Zuo, L., Meng, D., Qin, L., and Xu, X. (2011). Clinical observation of intravenous infusion of sophora after transcatheter arterial chemoembolization in treatment of mid-term liver cancer. Pract. J. Clin. Med. 11, 96-98.